Activation of tyrosine kinase of EGFR induces Gβγ-dependent GRK–EGFR complex formation  by Gao, Jingxia et al.
FEBS Letters 579 (2005) 122–126 FEBS 29095Activation of tyrosine kinase of EGFR induces Gbc-dependent
GRK–EGFR complex formation
Jingxia Gao, Jiali Li, Yuejun Chen, Lan Ma*
Pharmacology Research Center, Shanghai Medical College, Fudan University, 138 Yi Xue Yuan Road, Shanghai 200032, China
Received 23 September 2004; revised 10 November 2004; accepted 15 November 2004
Available online 30 November 2004
Edited by Veli-Pekka LehtoAbstract This study demonstrated that activation of tyrosine
kinase of epidermal growth factor receptor (EGFR) induces its
association with G protein-coupled receptor kinase 2 (GRK2).
Immunoprecipitation experiments showed that EGF stimulation
increased GRK2 binding to EGFR complex in HEK293 cells
coexpressing EGFR and GRK2. The EGF-induced GRK2–
EGFR complex formation was greatly reduced by perturbation
of EGFR and Src tyrosine kinase activity. Furthermore, studies
with GRK2 mutants showed that neither catalytic activity nor
the N-terminal domain of GRK2 was required for EGF-induced
GRK2–EGFR complex formation. However, overexpression of
Gbc scavengers blocked EGF-induced formation of GRK2–
EGFR complex.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphorylation1. Introduction
G protein-coupled receptors (GPCRs) constitute a super-
family of plasma membrane receptors, tranduce a large num-
ber of extracellular signals to the interior of cells, and play
fundamental roles in regulating various cellular functions [1].
Repeated GPCR activation triggers receptor desensitization
and the initial event of GPCR desensitization is GPCR phos-
phorylation catalyzed by GPCR kinases (GRKs) [2,3]. GPCR
phosphorylation promotes the binding of b-arrestins to the
receptor, which uncouples the receptor from its cognate G pro-
teins and induces subsequent GPCR internalizaiton and down-
regulation [3]. Thus, GRKs act as a critical modulator of
GPCR signaling.
Receptor tyrosine kinases (RTKs) constitute another large
family of plasma membrane receptors. RTKs play an impor-Abbreviations: EGF, Epidermal growth factor; EGFR, EGF receptor;
GPCR, G protein-coupled receptor; GRK, GPCR kinase; GRK2 D-
elN, GRK2 N-terminal deletion mutant; HA, hemagglutinin; HEK,
human embryonic kidney; SDS–PAGE, polyacrylamide gel electro-
phoresis in the presence of sodium dodecyl sulfate; PDGFR, Platelet-
derived growth factor receptor; GFP, green ﬂuorescent protein; PTX,
Pertussis Toxin
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doi:10.1016/j.febslet.2004.11.057tant role in the control of most fundamental cellular processes,
including cell cycle, proliferation and diﬀerentiation [4]. Epi-
dermal growth factor receptor (EGFR) belongs to RTKs
family. Binding of EGFR with its ligand induces autophos-
phorylation of its cytoplasmic domains, thus activating multi-
ple signaling cascades and ultimately inducing altered gene
expression in the nucleus [4]. EGFR signaling is modulated
by a number of mechanisms, including tyrosine dephosphoryl-
ation [5] and serine/threonine phosphorylation on the receptor
intracellular domain [6,7] as well as receptor internalization
and degradation [8,9]. Recent studies have demonstrated that
overexpression of GRK2 enhances EGF-stimulated ERK/
MAPK activation [10] and attenuates phosphoinositide hydro-
lysis, cell chemotaxis and proliferation evoked via platelet-de-
rived growth factor receptor b (PDGFRb) [11,12]. These data
demonstrate that GRKs also play an important role in regulat-
ing signal transduction mediated by RTKs. In vitro studies
have shown that puriﬁed GRK2 could catalyze phosphoryla-
tion of EGFR and PDGFRb on serine residues in an ago-
nist-promoted manner, and the association of GRK2 and
PDGFRb upon agonist stimulation in cells was detected [13].
However, the underlying molecular mechanisms of regulation
of RTK signaling by GRKs are not clear.2. Materials and methods
2.1. Reagents
Human EGF, Tyrphostin AG1478 (AG 1478), Pertussis toxin
(PTX), and [D-Pen2, D-Pen5] Enkephalin (DPDPE) were obtained
from Sigma. 4-Amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d]
pyrimidine (PP2) was purchased from Calbiochem. Modiﬁed Eagles
medium (MEM) and fetal bovine serum (FBS) were purchased from
Life Technologies, Inc. Protein A-Sepharose was obtained from Amer-
sham Pharmacia Biotech. Rabbit monoclonal antibody against FLAG
epitope and 12CA5 recognizing inﬂuenza hemagglutinin (HA) epitope
were supplied by Roche Molecular Biochemicals. Rabbit antibody
against EGFR was purchased from Santa Cruz Biotechnology, Inc.
Texas Red-conjugated goat anti-rabbit IgG was purchased from Jack-
son Immunoresearch (West Grove, PA). HRP-conjugated mouse
monoclonal antibody against phospho-tyrosine (pY20H) was supplied
by BD Biosciences Pharmingen. Mouse monoclonal antibody against
GRK2 was kindly provided by Dr. Martin Oppermann (Georg-August
University). Rabbit antibody against total and phospho-ERK were
supplied by New England Biolabs.
2.2. Plasmid construction
Plasmids encoding bovine GRK2, GRK2ct and transducin a were
prepared as described previously [14]. The catalytic inactive GRK2
mutant K220R and N-terminal 185 amino acid deletion mutant
GRK2 DelN were constructed by PCR mutagenesis, and the authen-
ticity of the sequences was conﬁrmed by DNA sequencing. Humanblished by Elsevier B.V. All rights reserved.
J. Gao et al. / FEBS Letters 579 (2005) 122–126 123EGFR cDNA with a FLAG tag was kindly provided by Dr. Neil J.
Freedman (Duke University Medical Center) and was subcloned into
pcDNA3 (Invitrogene). The wild type EGFR and EGFR tyrosine ki-
nase deﬁcient mutant EGFR K721A were generous gifts from
Dr. Sarah J. Parsons (University of Virginia) and were subcloned into
pcDNA3 with a sequence encoding a HA tag to generate EGFR with
an amino-terminal tag.2.3. Cell cultures and plasmid transfection
HEK293 cells (from American Type Culture Collection) were cul-
tured in MEM containing 10% fetal bovine serum and were seeded
in 60- or 100-mm tissue culture dishes at 1–3 · 106/dish 20 h before
transfection. Transfections of cells with 2–5 lg of each plasmid were
performed by calcium phosphate/DNA co-precipitation method. As-
says were performed 44–48 h after transfection and the cells were main-
tained overnight in FBS-free medium before the assay.2.4. Co-immunoprecipitation and Western procedures
The transfected HEK293 cells were stimulated with EGF at 37 C,
then washed with ice-cold PBS and lysed in 800 ll NP-40 solubilization
buﬀer (250 mM NaCl, 50 mM HEPES, 0.5% NP-40, 10% glycerol, 2
mM EDTA, pH 8.0, 1 mM Na3VO4, plus 10 lg/ml Aprotinin, 10
lg/ml Benzamidine, and 0.2 mM PMSF) as described [15] for 1.5 h.
The lysate was centrifuged, and the supernatant was incubated with
1 lg of anti-FLAG antibody and 15 ll of 50% slurry of protein A–
Sepharose beads at 4 C for 16 h. The beads were subsequently
washed, and the proteins bound to the beads were eluted in polyacryl-
amide gel electrophoresis in the presence of sodium dodecyl sulfate
(SDS–PAGE) sample buﬀer and separated by SDS–PAGE. The pres-
ence of EGFR, GRK2 in the immunoprecipitation complex was de-
tected in the subsequent Western procedures with corresponding
antibody. The immunoblots were visualized using an ECL kit. Direct
Western blot analysis of an aliquot (2.5%) of the cell lysate was done
to ensure equivalent expression level of the protein studied.Fig. 1. EGF stimulates GRK2–EGFR complex formation. HEK293
cells expressing GRK2–GFP or GRK2 and EGFR were stimulated
with 100 ng/ml EGF at 37 C for time as indicated. (A) The cells were
stained with anti-EGFR antibody and Texas Red-conjugated goat
anti-rabbit antibody, and analyzed under a laser confocal ﬂuorescence
microscope. The image overlay (yellow) was obtained by superimpo-
sition of the corresponding GRK2–GFP (green) images and EGFR
(red) images. (B) Immunoprecipitation of the receptor complex was2.5. Laser confocal ﬂuorescence microscopy
The cells grown on coverslips were stimulated with EGF at 37 C for
indicated time and ﬁxed, then incubated with anti-EGFR antibody (1
lg/ml) in PBS containing 1% bovine serum albumin for 2 h at room
temperature and washed with PBS. The cells were incubated with
Texas Red-conjugated goat anti-rabbit antibody (1 lg/ml) at room
temperature for 1 h and washed with PBS. The coverslips were then
mounted onto microscope slides with 50% glycerol in PBS. Scanning
images were recorded with a TCS NT laser confocal ﬂuorescence
microscope (Leica Microsystems, Bensheim, Germany).carried out using anti-FLAG antibody. EGFR immunoprecipitation
complex and the cell lysates were resolved by SDS–PAGE, and
electrotransferred onto nitrocellulose membranes. The upper and the
lower parts of the same membrane were probed with antibodies against
FLAG and GRK2, respectively. Direct Western blot analysis of the
lysate was done to ensure equivalent expression level of FLAG-EGFR
and GRK2.3. Results
3.1. EGF stimulates GRK2–EGFR complex formation
HEK293 cells were transfected with GRK2–green ﬂuores-
cent protein (GFP) and EGFR encoding plasmids, and the
change of the subcellular distribution of GRK2 after EGF
stimulation was examined using laser confocal ﬂuorescence
microscopy. GRK2–GFP was mainly distributed in the cyto-
plasm before EGF stimulation. However, after incubation
with EGF, GRK2–GFP translocated to plasma membrane
and became colocalized with EGFR (Fig. 1A). The potential
association of GRK2 with EGFR in HEK293 cells transiently
expressing EGFR and GRK2 was examined in immunoprecip-
itation experiments. As shown in Fig. 1B, little GRK2 was de-
tected in the EGFR immunoprecipitation complex in the
absence of EGF stimulation. After treatment with EGF, a
large amount of GRK2 could be detected in the EGFR immu-
noprecipitation complex. The amount of GRK2 in the EGFR
immunoprecipitation complex reached maximum at 5 min of
EGF stimulation and then decreased. These results clearly
demonstrated that EGF stimulation could induce transloca-tion of GRK2 from cytoplasm to the plasma membrane and
the formation of GRK2–EGFR complex in a time-dependent
manner.
3.2. EGF-induced GRK2–EGFR complex formation requires
tyrosine kinase activity of EGFR and Src
We next explored the role of receptor tyrosine phosphoryla-
tion in EGF-induced GRK2–EGFR complex formation. As
shown in Fig. 2A, EGF stimulation induced a remarkable in-
crease in tyrosine phosphorylation of EGFR and also induced
the formation of GRK2–EGFR complex. Pretreatment with
AG 1478, a speciﬁc inhibitor of EGFR tyrosine kinase, ro-
bustly inhibited both EGF-induced EGFR tyrosine phosphor-
ylation and EGF-stimulated GRK2 binding to EGFR
complex (Fig. 2A). The role of the tyrosine kinase activity
Fig. 2. EGF-induced GRK2–EGFR complex formation requires
tyrosine kinase activity of EGFR and Src. (A) HEK293 cells
expressing FLAG-EGFR and GRK2 were treated with or without
100 nM AG 1478 for 20 min before stimulating with 100 ng/ml EGF
for 5 min. Immunoprecipitation of the receptor complex and Western
blot analysis were carried out as described in Fig. 1 except that after
being probed with anti-FLAG antibody the upper parts of the
membrane were stripped and reprobed with pY20H. (B) HEK293 cells
expressing GRK2 and HA-EGFR or HA-EGFR K721A were treated
as described in A except that the cells were not pretreated with AG
1478. (C) HEK293 cells expressing FLAG-EGFR and GRK2 were
treated as described in A except that the cells were pretreated with or
without 5 lM PP2 for 20 min. Pictures shown are representatives of
three independent experiments performed.
Fig. 3. EGF-induced GRK2–EGFR complex formation requires
neither GRK2 catalytic activity nor N-terminal domain of GRK2.
HEK293 cells expressing FLAG-EGFR and GRK2, GRK2 K220R or
GRK2 DelN were stimulated with 100 ng/ml EGF. Immunoprecipi-
tation of the receptor complex and Western blot analysis were carried
out. Pictures shown are representatives of three independent experi-
ments performed.
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mutant EGFR K721A. As shown in Fig. 2B, EGF stimulationfailed to induce either tyrosine phosphorylation of HA-EGFR
K721A or GRK2 binding to EGFR K721A complex. These
results clearly demonstrate that EGF-induced GRK2–EGFR
complex formation requires tyrosine kinase activity of EGFR.
Next we explored the role of Src tyrosine kinase, a signal
molecule activated by EGF stimulation [16], in EGF-induced
GRK2–EGFR complex formation. As shown in Fig. 2C, pre-
treatment of the cells with PP2, a speciﬁc inhibitor of Src tyro-
sine kinase, greatly decreased EGF-induced GRK2–EGFR
complex formation. This result indicates that EGF-induced
GRK2–EGFR complex formation requires Src activity.
3.3. EGF-induced GRK2–EGFR complex formation requires
neither GRK2 catalytic activity nor N-terminal domain of
GRK2
GRK2 K220R is a kinase dominant negative mutant of
GRK2 and inhibits phosphorylation of various GPCRs medi-
ated by the wild type GRK2 [17,18]. Our co-immunoprecipita-
tion experiments (Fig. 3) revealed a strong association of
GRK2 K220R with EGFR complex. Moreover, the amount
of GRK2 K220R in the receptor complex was more than that
of the wild type GRK2 both in the presence and absence of
EGF stimulation. The N-terminal domain (consisting of 185
residues) of GRK2 plays an important role in the interaction
with agonist-activated GPCR [19]. The results of co-immuno-
precipitation showed that GRK2 DelN, which lacks the N-ter-
minal 185 amino acid residues, was detected in the EGFR
immunoprecipitation complex both in the presence and ab-
sence of EGF stimulation and EGF strongly augmented the
amount of GRK2 DelN in the EGFR immunoprecipitation
complex (Fig. 3). These data indicate that neither the catalytic
activity nor the N-terminal domain of GRK2 is required for
EGF-induced GRK2–EGFR complex formation.
Fig. 4. EGF-induced GRK2–EGFR complex formation requiresf free
Gbc subunits. (A) The HEK293 cells transfected with plasmids as
indicated were treated with or without 100 ng/ml PTX for 18 h before
stimulating with 100 ng/ml EGF. Immunoprecipitation of the receptor
complex and Western blot analysis were carried out. (B) HEK293 cells
were stimulated with EGF for 5 min and HEK293 cells stably
expressing d opioid receptor were stimulated with DPDPE for 5 min
following pretreatment with or without PTX. Cell lysates were
subjected to Western blot analysis. The blots were probed with
phospho-ERK antibody, and then reprobed with total-ERK antibody
after stripping to serve as a loading control. Pictures shown are
representatives of three independent experiments performed.
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free Gbc subunits
Co-immunoprecipitation experiments showed that pretreat-
ment of PTX, a speciﬁc inhibitor of Gi/o protein, did not sig-
niﬁcantly aﬀect EGF-induced formation of GRK2–EGFR
complex and ERK phosphorylation (Fig. 4). In a control
experiment, Gi/o-mediated ERK phosphorylation [20] induced
by DOR agonist DPDPE was robustly inhibited by PTX (Fig.
4B). Co-immunoprecipitation experiments (Fig. 4A) also
showed that when the cells were transfected with Gbc scaveng-
ers Gta or GRK2ct [14,19], the amount of GRK2 detected in
the EGFR immunoprecipitation complex induced by EGF was
greatly decreased. These results indicate that EGF-induced
GRK2–EGFR complex formation requires free Gbc subunits,
but PTX-sensitive G protein activation was not required, at
least in HEK293 cells.4. Discussion
Accumulating evidence has demonstrated that GRK2 is a
novel modulator of RTK-mediated signal transduction
[11,12]. The current study explored the potential mechanisms
underlying GRKs regulation on EGF-mediated signal trans-
duction. Our results have shown that EGF stimulates GRK–
EGFR complex formation. Moreover, EGFR and Src tyrosine
kinase activity as well as the free Gbc subunits are required in
this complex formation. However, neither the catalytic activity
nor the N-terminal domain of GRK2 is required.Tyrosine kinase activity of EGFR is critical for EGFR sig-
naling. Research has shown that EGFR kinase deﬁcient mu-
tant EGFR K721A preserves the normal ligand-binding
properties as its wild-type counterpart does, but loses almost
all measurable cellular responses to EGF [21]. Our data
showed that inhibition of tyrosine kinase activity of EGFR
either by speciﬁc EGFR tyrosine kinase inhibitor or by mutat-
ing residues in EGFR critical for its catalytic function could
eﬀectively block EGF-stimulated GRK binding to EGFR
complex, demonstrating that receptor activation and the tyro-
sine kinase activity of EGFR are required for GRK2–EGFR
complex formation. Previous study with puriﬁed GRK has
shown that GRK2 fails to phosphorylate PDGFRb K634R,
a kinase deﬁcient mutant of PDGFR [13]. Our results are in
accordance with that and suggest that the absence of GRK–
RTK complex formation may account for the absence of ser-
ine phosphorylation of RTKs by GRK2.
Our present study demonstrates the formation of GRK2–
EGFR complex upon EGF stimulation, but whether GRK2
binds to EGFR directly or indirectly needs to be further inves-
tigated. A recent study has shown that puriﬁed GRK2 pro-
motes serine phosphorylation of EGFR and PDGFRb, and
overexpression of GRK2 in cells yields similar result, suggest-
ing that RTKs are novel substrates of GRK2 [13]. GRK2
interacts directly with activated GPCR through its N-terminal
domain [19], but our results showed that such domain is not
required in GRK2–EGFR complex formation. There is no
SH2 domain identiﬁed in GRK, but a recent study has shown
that EGF stimulation promotes the association of GRK2 with
Src-PDEc preformed complex to form GRK2–Src-PDEc com-
plex, and GRK2 phosphorylates PDEc in EGF-dependent
manner to potentiate EGF-induced ERK activation [10]. In
addition, activated Src tyrosine kinase can phosphorylate
GRK2 on its tyrosine residue, leading to increased kinase
activity of GRK2 [22]. Our results revealed that the EGF-in-
duced GRK2–EGFR complex formation requires Src activity,
suggesting that GRK2–EGFR complex formation may involve
Src.
The present study has also shown that EGF-induced
GRK2–EGFR complex formation requires free Gbc subunits,
which resembles the case of GPCR. Upon GPCR activation,
GRK2 binds to liberated Gbc dimers to be recruited to the
activated GPCRs to form GPCR–GRK complex on the mem-
brane [23]. A recent study has shown that GPCR activation in-
duces formation of GPCR–GRK–Gbc multiple complex,
which is required for kinase activity of GRK2 [14]. Our results
showed that Gbc subunits scavengers blocked the formation of
EGF-induced GRK2–EGFR complex, suggesting that
GRK2–EGFR complex may also contain Gbc subunits. Our
study showed that at least in HEK293 cells, PTX-sensitive G
protein activation is not required for GRK2–EGFR complex
formation, indicating that PTX-sensitive G protein is not the
main source of free Gbc subunits required for EGF-induced
GRK2–EGFR complex formation. Previous studies [24,25]
have shown that EGF stimulation can activate G proteins
other than PTX-sensitive Gi/o proteins and if activation of
these G proteins is involved in EGF-induced GRK2–EGFR
complex formation is an interesting issue demanding further
research. Our research demonstrates that EGF-induced
GRK2–EGFR complex formation requires EGFR and Src
tyrosine kinase activity and free Gbc subunits, suggesting that
activation of tyrosine kinase of EGFR induces the formation
126 J. Gao et al. / FEBS Letters 579 (2005) 122–126of a large multi-component complex and the receptor complex
may contain Src, Gbc subunits and other signaling molecules
such as PDEc in addition to GRK2. However, many members
of the complex are to be identiﬁed and the roles of the EGF-
induced receptor complex in the regulation of EGFR- and
other receptor-mediated signaling pathways need to be ex-
plored further.
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